ORBIMED ADVISORS LLC - 24 Jun 2025 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Reporting relationship: 10%+ Owner
Issuer ticker: PASG
Reported as of: 24 Jun 2025
Net transaction value: -$197,239
SEC form: 4
Accepted by SEC: 26 Jun 2025, 17:10:11 UTC
Prior SEC filing: 16 May 2025
Next SEC filing: 01 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Passage BIO, Inc. (PASG) on 26 Jun 2025.

Key facts

This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Passage BIO, Inc. (PASG).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Jun 2025, 17:10.

Change

Previous filing in this sequence was filed on 16 May 2025.
Current net transaction value: -$197,239.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001055951 Primary reporting owner

ORBIMED ADVISORS LLC

Relationship: 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Signature date: 26 Jun 2025

CIK 0001760648

OrbiMed Capital GP VII LLC

Relationship: 10%+ Owner
Address: 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature: /s/ Carl L. Gordon, Member of OrbiMed Capital GP VII LLC
Signature date: 26 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PASG transaction

Common Stock

Sale

Transaction value: $81,060
Shares: -231,600
Change %: -3.5%
Price: $0.3500
Shares after: 6,418,400
Date: 24 Jun 2025
Ownership: See footnotes
Footnotes: F1, F2

PASG transaction

Common Stock

Sale

Transaction value: $45,804
Shares: -138,800
Change %: -2.2%
Price: $0.3300
Shares after: 6,279,600
Date: 25 Jun 2025
Ownership: See footnotes
Footnotes: F1, F2

PASG transaction

Common Stock

Sale

Transaction value: $70,375
Shares: -213,257
Change %: -3.4%
Price: $0.3300
Shares after: 6,066,343
Date: 26 Jun 2025
Ownership: See footnotes
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

ORBIMED ADVISORS LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

These shares of the Issuer's common stock are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the shares of common stock held by OPI VII and, as a result, may be deemed to have beneficial ownership over such shares of common stock. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership over the shares of common stock held by OPI VII.

Footnote F2

Each of OrbiMed Advisors and GP VII disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.